<DOC>
	<DOCNO>NCT02185300</DOCNO>
	<brief_summary>Dolutegravir ( DTG ) HIV-1 integrase inhibitor approve United States , Canada , Australia EU . A dispersible tablet develop pediatric use alternative granule formulation , already development , approve film-coated tablet . This single-center , randomize , open-label , 5-way crossover study healthy adult subject . The study evaluate relative bioavailability five dosing regimen : 20 mg DTG pediatric granule ( Treatment A ) DTG 20 mg dispersible tablet ( DTG 20 mg DT ) disperse : low mineral content ( LMC ) water ( Treatment B ) ; disperse CONTREX™ mineral water ( Treatment C ) ; disperse low mineral content water consume stand 30 minute ( Treatment D ) disperse CONTREX mineral water consume stand 30 minute ( Treatment E ) . Safety evaluations serial PK sample collect treatment period . A follow-up visit occur 7-14 day last dose study drug . CONTREX trademark Nestlé Waters Corporation .</brief_summary>
	<brief_title>Bioavailability Study Dolutegravir Dispersible Tablet Effect Different Types Water Dispersible Tablet Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Inclusion Criteria Males female age 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include Investigator agree document find unlikely introduce additional risk factor interfere study procedure . Body weight +/ 50 kilogram ( kg ) males +/ 45 kg female body mass index ( BMI ) within range 18.5 31.0 kilogram/square meter ( kg/m^2 ) ( inclusive ) . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation , bilateral salpingectomy , bilateral oophorectomy hysterectomy definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; postmenopausal define 12 month spontaneous amenorrhea questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter ( mIU/mL ) estradiol &lt; 40 picograms per milliliter ( pg/ml ) ( &lt; 147 picomole/liter [ pmol/L ] ) confirmatory . Childbearing potential negative pregnancy test determine serum urine human chorionic gonadotropin ( hCG ) test screen prior dosing AND agree use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 5 day postlast dose OR samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form . Alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; = 1.5x upper limit normal range ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . A single repeat screen period 1 , day 1 allow eligibility determination . QT duration correct heart rate ( QTc ) &lt; 450 millisecond ( msec ) , use Bazett Correction Formula , QT correction use Bazett Formula ( QTcB ) . A single repeat screen period 1 , day 1 allow eligibility determination . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Pregnant female determine positive serum urine hCG test screen prior dosing . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram ( g ) alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Lactating female . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Regular use tobacco nicotinecontaining product within 60 day prior screen . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St. John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . The subject 's systolic blood pressure outside range 90140 millimeter mercury ( mmHg ) , diastolic pressure outside range 4590 mmHg , heart rate outside range 50100 beat per minute ( bpm ) female subject 45110 bpm male subject . A single repeat screen period 1 , day 1 allow eligibility determination . Exclusion criterion screen electrocardiogram ( ECG ) ( single repeat allow eligibility determination ) : Heart rate For male &lt; 45 &gt; 110 bpm female &lt; 50 &gt; 100 bpm , PR Interval &lt; 120 &gt; 220 msec , QRS duration &lt; 70 &gt; 120 msec , QTc interval ( Bazett ) &gt; 450 msec , evidence previous myocardial infarction ( Does include ST segment change associate repolarization ) , clinically significant arrhythmia , opinion investigator GSK Medical Monitor , interfere safety individual subject , conduction abnormality exception 1st degree atrioventricular block incomplete right bundle branch block</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>GSK1349572</keyword>
	<keyword>granule</keyword>
	<keyword>pediatric</keyword>
	<keyword>CONTREX mineral water</keyword>
	<keyword>free-acid</keyword>
	<keyword>chelate</keyword>
	<keyword>cation</keyword>
	<keyword>divalent</keyword>
	<keyword>dolutegravir</keyword>
	<keyword>dispersible tablet</keyword>
	<keyword>relative bioavailability</keyword>
</DOC>